Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a 3-year-old boy diagnosed with temporal triangular alopecia, emphasizing the importance of clinical and dermoscopic examination for correct diagnosis due to the condition's rarity and risk of misdiagnosis.

People with hair loss often experience lower quality of life, depression, and self-esteem issues.

In this study, baricitinib treatment improved the differentiation of skin-derived precursors into adipocytes for diseases like Hutchinson-Gilford progeria syndrome, suggesting potential benefits when combined with lonafarnib.

In this study, Scalp Immersion Proxigraphy (SIP) was shown to produce more accurate measurements of linear hair growth rate than crude phototrichogram techniques, suggesting SIP's suitability for clinical trials monitoring hair growth.

In this case study of a Beetal doe with severe skin lesions, the researchers diagnosed concurrent psoroptic mange and malasseziosis, and reported successful treatment with a combination of Ivermectin, antibiotics, and topical applications, leading to reduced skin lesions and new hair growth.

Tigason improved hair growth in a boy with monilethrix without side effects.

This study found that among adult balding men in Rawalpindi and Islamabad, those seeking hair transplants exhibited higher levels of perfectionism and body dysmorphic disorder symptoms compared to those not seeking treatment.

This study found that adding 10 mg/day of biotin to isotretinoin treatment for acne improved hair growth and maintained skin hydration, potentially reducing isotretinoin's mucocutaneous side effects.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This study found that calcitriol-resistant rickets is associated with alopecia in children and should be considered in the differential diagnosis of hair loss.

This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.

This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.

Tofacitinib might be used to treat hair loss.

This paper reviews the diverse skin, nail, and hair changes caused by medications, highlighting hyperpigmentation, alopecia, and nail structural alterations, but reports no new data.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This study reports that over one-quarter of dermatology outpatients show psychiatric morbidity, highlighting the importance of considering psychological factors in managing skin diseases.

In this case report, a 60-year-old man with rheumatoid arthritis and sudden hair whitening was treated with baricitinib, showing significant hair repigmentation and regrowth in 8 months, suggesting potential for baricitinib in managing canities subita, especially when linked to alopecia areata.

This study found that negative illness perception in Saudi patients with alopecia is linked to reduced quality of life and increased anxiety and depression, highlighting the importance of addressing both physical and mental health in treatment.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

This source reported that patients who initially responded to ritlecitinib treatment showed sustained hair regrowth through week 48, with up to one-third of those not meeting target efficacy at week 24 also achieving a response with continued treatment.

This review by Aceituno et al. found that both baricitinib and ritlecitinib demonstrate strong efficacy for severe alopecia areata, with meaningful hair regrowth by Week 24, but notes limitations like differing trial sizes and potential effect size overestimations.

The document's conclusion cannot be summarized because the content is not accessible or understandable.

This case report describes a 30-year-old woman with keratosis pilaris treated with emollients and keratolytics, resulting in slight improvement.

This study describes a patient with Rothmund–Thomson syndrome-like symptoms who displayed hair improvement after combination therapy, despite carrying an ANAPC1 gene variant of uncertain significance.